Coherus Oncology (CHRS) EBITDA (2013 - 2026)

Coherus Oncology has disclosed EBITDA across 14 years of filings, most recently posting -$32.3 million for Q2 2026.

• In Q2 2026, EBITDA rose 28.92% year-over-year to -$32.3 million; the TTM figure through Jun 2026 stood at -$158.7 million (up 13.36% YoY), while the FY2025 annual figure was -$181.1 million, up 9.28% from the prior year.
• EBITDA came in at -$32.3 million for Q2 2026 at Coherus Oncology, up from -$36.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$32.0 million in Q3 2023 to a low of -$80.9 million in Q1 2022.
• Average EBITDA over 5 years is -$50.5 million, with a median of -$45.5 million recorded in 2025.
• Year-over-year, EBITDA tumbled 145.37% in 2022 and jumped 60.22% in 2023.
• Over 5 years, EBITDA stood at -$51.5 million in 2022, then tumbled by 33.81% to -$68.9 million in 2023, then jumped by 34.14% to -$45.4 million in 2024, then dropped by 1.09% to -$45.9 million in 2025, then advanced by 29.53% to -$32.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$32.3 million in Q2 2026, -$36.2 million in Q1 2026, and -$45.9 million in Q4 2025.